Inxight Drugs

Search results for momelotinib in Any Name (approximate match)

Showing 1 - 10 of 12 results

MOMELOTINIB

MORE DETAILS

6O01GMS00P

Search for Structure

Status:

US Approved Rx (2023)

First approved in 2023

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Momelotinib (CYT387) is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases. Momelotinib is developing by Gilead Sciences for the oral treatment of pancreatic and non-small cell lung cancers, and myeloproliferative disorders (including myelofibrosis, essential thrombocythaemia and polycythaemia vera).

Search results for momelotinib in Any Name (approximate match)

Showing 1 - 10 of 12 results

MOMELOTINIB

4-(2-(4-(3-OXOMORPHOLIN-4-YL)ANILINO)PYRIMIDIN-4-YL)BENZAMIDE

4-[2-[(4-Aminophenyl)amino]-4-pyrimidinyl]-N-(cyanomethyl)benzamide

N-(CYANOMETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE

2-(N-(CARBOXYMETHYL)-4-((4-(4-(CYANOMETHYLCARBAMOYL)PHENYL)PYRIMIDIN-2-YL)AMINO)ANILINO)ACETIC ACID

BENZOIC ACID, 4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-

BENZAMIDE, N-(CYANOMETHYL)-4-(2-((4-((2-HYDROXYETHYL)AMINO)PHENYL)AMINO)-4-PYRIMIDINYL)-

N-(2-AMINO-2-OXO-ETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE

4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZOIC ACID

BENZAMIDE, N-(2-AMINO-2-OXOETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-

Showing 1 - 10 of 12 results